Ajanta Pharma has informed that in furtherance to intimation dated March 10, 2023 informing the stock exchanges with respect to Buy-back of 22,10,500 shares of the Company at a price of Rs 1,425 per equity share, on a proportionate basis, through the tender offer process ('Buyback'), in accordance with the provisions of the Companies Act, 2013, and rules made thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (the 'SEBI Buyback Regulations') as amended from time to time and other applicable laws, the Company has enclosed: (a) A copy of the Public Announcement, as published in newspapers; and (b) Certified true copy of the resolution passed by the Board of Directors on dated March 10 2023 for approving the proposal of Buyback.
The above information is a part of company’s filings submitted to BSE.
